skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A Phase I Study of Chemoradiotherapy With Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small Cell Lung Cancer: WJTOG 3305

Abstract

Purpose: A Phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small-cell lung cancer was conducted. Methods and Materials: Patients with unresectable Stage III non-small-cell lung cancer were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m{sup 2}) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m{sup 2}). Total doses were 54 Gy in 36 fractions, 60 Gy in 40 fractions, 66 Gy in 44 fractions, and 72 Gy in 48 fractions at Levels 1 to 4. The dose-limiting toxicity, defined as Grade {>=}4 esophagitis and neutropenic fever and Grade {>=}3 other nonhematologic toxicities, was monitored for 90 days. Results: Of 26 patients enrolled, 22 patients were assessable for response and toxicity. When 4 patients entered Level 4, enrollment was closed to avoid severe late toxicities. Dose-limiting toxicities occurred in 3 patients. They were Grade 3 neuropathy at Level 1 and Level 3 and Grade 3 infection at Level 1. However, the maximum tolerated dose was not reached.more » The median survival time was 28.6 months for all patients. Conclusions: The maximum tolerated dose was not reached, although the dose of radiation was escalated to 72 Gy in 48 fractions. However, a dose of 66 Gy in 44 fractions was adopted for this study because late toxicity data were insufficient.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [7];  [8];  [9];  [10];  [11];  [12]
  1. Department of Radiology, Osaka City University Graduate School of Medicine, Osaka (Japan)
  2. (Japan)
  3. Department of Environmental Medicine and Behavioural Science, Kinki University Faculty of Medicine, Osaka-sayama (Japan)
  4. Department of Radiation Oncology, Hyogo Cancer Center, Akashi (Japan)
  5. Department of Radiology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino (Japan)
  6. Department of Radiation Oncology, Kinki University Faculty of Medicine, Osaka-sayama (Japan)
  7. Division of Radiation Oncology, Institute of Biomedical Research and Innovation, Kobe (Japan)
  8. Department of Medical Oncology, Hyogo Cancer Center, Akashi (Japan)
  9. Department of Respiratory Medicine, Osaka City University Graduate School of Medicine, Osaka (Japan)
  10. Department of Medical Oncology, Izumi Municipal Hospital, Izumi (Japan)
  11. Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-sayama (Japan)
  12. Research Institute for Disease of the Chest, Graduate School of Medical Science, Kyusyu University, Fukuoka (Japan)
Publication Date:
OSTI Identifier:
22056352
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 83; Journal Issue: 1; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CHEMOTHERAPY; COMBINED THERAPY; FEVER; LUNGS; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIOTHERAPY; SURVIVAL TIME; TOXICITY

Citation Formats

Tada, Takuhito, E-mail: tada@msic.med.osaka-cu.ac.jp, Department of Radiology, Izumi Municipal Hospital, Izumi, Chiba, Yasutaka, Tsujino, Kayoko, Fukuda, Haruyuki, Nishimura, Yasumasa, Kokubo, Masaki, Negoro, Shunichi, Kudoh, Shinzoh, Fukuoka, Masahiro, Nakagawa, Kazuhiko, and Nakanishi, Yoichi. A Phase I Study of Chemoradiotherapy With Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small Cell Lung Cancer: WJTOG 3305. United States: N. p., 2012. Web. doi:10.1016/J.IJROBP.2011.06.1991.
Tada, Takuhito, E-mail: tada@msic.med.osaka-cu.ac.jp, Department of Radiology, Izumi Municipal Hospital, Izumi, Chiba, Yasutaka, Tsujino, Kayoko, Fukuda, Haruyuki, Nishimura, Yasumasa, Kokubo, Masaki, Negoro, Shunichi, Kudoh, Shinzoh, Fukuoka, Masahiro, Nakagawa, Kazuhiko, & Nakanishi, Yoichi. A Phase I Study of Chemoradiotherapy With Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small Cell Lung Cancer: WJTOG 3305. United States. doi:10.1016/J.IJROBP.2011.06.1991.
Tada, Takuhito, E-mail: tada@msic.med.osaka-cu.ac.jp, Department of Radiology, Izumi Municipal Hospital, Izumi, Chiba, Yasutaka, Tsujino, Kayoko, Fukuda, Haruyuki, Nishimura, Yasumasa, Kokubo, Masaki, Negoro, Shunichi, Kudoh, Shinzoh, Fukuoka, Masahiro, Nakagawa, Kazuhiko, and Nakanishi, Yoichi. Tue . "A Phase I Study of Chemoradiotherapy With Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small Cell Lung Cancer: WJTOG 3305". United States. doi:10.1016/J.IJROBP.2011.06.1991.
@article{osti_22056352,
title = {A Phase I Study of Chemoradiotherapy With Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small Cell Lung Cancer: WJTOG 3305},
author = {Tada, Takuhito, E-mail: tada@msic.med.osaka-cu.ac.jp and Department of Radiology, Izumi Municipal Hospital, Izumi and Chiba, Yasutaka and Tsujino, Kayoko and Fukuda, Haruyuki and Nishimura, Yasumasa and Kokubo, Masaki and Negoro, Shunichi and Kudoh, Shinzoh and Fukuoka, Masahiro and Nakagawa, Kazuhiko and Nakanishi, Yoichi},
abstractNote = {Purpose: A Phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small-cell lung cancer was conducted. Methods and Materials: Patients with unresectable Stage III non-small-cell lung cancer were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m{sup 2}) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m{sup 2}). Total doses were 54 Gy in 36 fractions, 60 Gy in 40 fractions, 66 Gy in 44 fractions, and 72 Gy in 48 fractions at Levels 1 to 4. The dose-limiting toxicity, defined as Grade {>=}4 esophagitis and neutropenic fever and Grade {>=}3 other nonhematologic toxicities, was monitored for 90 days. Results: Of 26 patients enrolled, 22 patients were assessable for response and toxicity. When 4 patients entered Level 4, enrollment was closed to avoid severe late toxicities. Dose-limiting toxicities occurred in 3 patients. They were Grade 3 neuropathy at Level 1 and Level 3 and Grade 3 infection at Level 1. However, the maximum tolerated dose was not reached. The median survival time was 28.6 months for all patients. Conclusions: The maximum tolerated dose was not reached, although the dose of radiation was escalated to 72 Gy in 48 fractions. However, a dose of 66 Gy in 44 fractions was adopted for this study because late toxicity data were insufficient.},
doi = {10.1016/J.IJROBP.2011.06.1991},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 1,
volume = 83,
place = {United States},
year = {Tue May 01 00:00:00 EDT 2012},
month = {Tue May 01 00:00:00 EDT 2012}
}